The development of a technology-based information support intervention (iSupport) among patients with differentiated thyroid cancer post radioactive iodine therapy

针对放射性碘治疗后分化型甲状腺癌患者开发基于技术的信息支持干预 (iSupport)

基本信息

  • 批准号:
    10581121
  • 负责人:
  • 金额:
    $ 13.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-03-02 至 2025-02-28
  • 项目状态:
    未结题

项目摘要

Abstract Radioactive iodine (RAI) therapy is routinely used among patients diagnosed with differentiated thyroid cancer (DTC), with approximately 76% of patients receiving RAI. Patients with DTC post RAI treatment report extensive short-term and late effects of treatment, symptom burden, and unmet informational needs about treatment related side effects. However, thyroid cancer is frequently referred to as the “good cancer” and is an understudied cancer population for survivorship research and web-based interventions. One way to address these gaps is through digital technologies such as a web-based intervention, which can empower patients with direct access to educational and support tools to reduce symptom burden. I propose to develop and evaluate a web-based intervention, called iSupport (informational support among patients post RAI treatment), to reduce symptom burden among patients diagnosed with DTC post RAI. I propose the following aims: Aim 1 (K99). Develop iSupport, a web-based intervention, for patients with DTC post RAI therapy. Aim 2 (K99). Test the usability of the newly developed iSupport intervention among patients with DTC post RAI. Aim 3 (R00). Assess the feasibility and acceptability of the iSupport intervention. Aim 4 (R00). Test the preliminary efficacy of the iSupport intervention vs. treatment as usual (TAU) among patients with DTC on symptom burden. The K99 phase will involve: 1) conducting patient focus groups (N=32) and individual stakeholder interviews (N=12) to develop iSupport and 2) testing the usability of the iSupport intervention among patients with DTC post RAI therapy (N=8). The R00 phase will involve conducting a pilot randomized controlled trial (RCT; N=72) to: 1) assess the feasibility and acceptability of iSupport and 2) test the preliminary efficacy of iSupport compared to a (TAU) control group with DTC patients on RAI-related symptom burden, patient bioheath indicators (oral mucositis; oral health problems), knowledge of DTC and RAI, self-efficacy for coping with side effects, cancer- related distress, and health-related quality of life. The overall objective of the K99/R00 is to provide Dr. Carr with training and mentorship to become an independent cancer control investigator with expertise in digital technology evidenced-based interventions among cancer patients. The K99 training goals include: 1) increase knowledge of clinical concerns and symptoms among patients with DTC post RAI, 2) obtain advanced training in technology-based intervention design and development, 3) develop expertise in behavioral intervention clinical trials design and testing, and 4) refine grant writing and leadership skills for future independence. Dr. Carr’s mentorship team includes Drs. Kristi Graves (primary), Jacqueline Jonklaas (co-mentor), and Kristen Miller (co-mentor) who are committed to her career development. The proposed training plan will facilitate Dr. Carr’s transition to independence as a cancer control researcher with expertise in digital health interventions to reduce symptom burden and improve health-related quality of life in cancer patient outcomes after treatment.
摘要 放射性碘(RAI)治疗通常用于诊断为分化型甲状腺癌的患者 (DTC),约76%的患者接受RAI。RAI治疗后DTC患者报告 治疗的广泛短期和晚期影响、症状负担以及未满足的信息需求 治疗相关的副作用。然而,甲状腺癌经常被称为“好癌症”,是一种恶性肿瘤。 研究不足的癌症人群进行生存研究和基于网络的干预措施。一种方法来解决 这些差距是通过数字技术,如基于网络的干预,这可以使患者 直接获得教育和支持工具,以减轻症状负担。我建议开发和评估一个 基于网络的干预,称为iSupport(RAI治疗后患者之间的信息支持),以减少 RAI后诊断为DTC患者的症状负担。我提出以下目标:目标1(K99)。 为RAI治疗后的DTC患者开发iSupport,一种基于网络的干预。目标2(K99)。测试 新开发的iSupport干预在RAI后DTC患者中的可用性。目标3(R 00)。 评估iSupport干预的可行性和可接受性。目标4(R 00)。检验初步疗效 iSupport干预与常规治疗(TAU)在DTC患者中的症状负担。的 K99阶段将包括:1)进行患者焦点小组(N=32)和个体利益相关者访谈(N=12) 开发iSupport和2)在RAI后DTC患者中测试iSupport干预的可用性 治疗(N=8)。R 00阶段将涉及进行一项初步随机对照试验(RCT; N=72),以:1) 评估iSupport的可行性和可接受性; 2)测试iSupport的初步有效性, a(TAU)对照组DTC患者的RAI相关症状负担、患者生物健康指标(口服 口腔健康问题)、DTC和RAI知识、应对副作用的自我效能、癌症- 与健康相关的生活质量。K99/R 00的总体目标是为卡尔博士提供 通过培训和指导,成为一名独立的癌症控制调查员, 在癌症患者中进行基于证据的技术干预。K99培训目标包括:1)增加 了解RAI后DTC患者的临床问题和症状,2)获得高级培训 在基于技术干预设计和开发中,3)发展行为干预方面的专业知识 临床试验设计和测试,以及4)完善拨款写作和领导技能,以确保未来的独立性。博士 卡尔的导师团队包括博士克里斯蒂格雷夫斯(主要),杰奎琳Jonklaas(共同导师),和克里斯汀 米勒(共同导师)谁是致力于她的职业发展。拟议的培训计划将有助于博士。 卡尔的过渡到独立作为一个癌症控制研究人员与数字健康干预的专业知识, 减轻症状负担,改善癌症患者治疗后的健康相关生活质量。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alaina L Carr其他文献

Alaina L Carr的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 13.1万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 13.1万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 13.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 13.1万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 13.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 13.1万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 13.1万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 13.1万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 13.1万
  • 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
  • 批准号:
    2706416
  • 财政年份:
    2022
  • 资助金额:
    $ 13.1万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了